Nilotinib Drug Profile | PharmaGraphX

Boxed warning

QT prolongation and sudden death reported

Clinical alerts

Boxed warning

1 boxed warning

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Selectively inhibits BCR-ABL kinase; more potent than imatinib

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Advanced Malignant Solid Neoplasm
·Anatomic Stage III Breast Cancer AJCC v8
·Anatomic Stage IV Breast Cancer AJCC v8
·Locally Advanced Malignant Solid Neoplasm
·Malignant Female Reproductive System Neoplasm

Interactions

No curated interaction pairs are recorded for Nilotinib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Rash
Headache
Nausea
Fatigue
Myelosuppression

Food, alcohol & herbal

Food

Must take on empty stomach — food increases absorption 82% (risk of QT prolongation)

Alcohol · moderate

Additive hepatotoxicity

Pharmacokinetics

Half-life: 17 hours
Protein binding: 98%
Metabolised by: CYP3A4, CYP2C8
Inhibits: CYP3A4, CYP2C8, CYP2D6

Pregnancy & lactation

Not recorded for Nilotinib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.